Solventum Corporation (SOLV) News
Follow Solventum Corporation (SOLV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Solventum Reports Third-Quarter Revenue of $1.95 Billion, Raises 2026 EPS Guidance
Solventum reported adjusted EPS of $1.45 and raised its full-year 2026 adjusted EPS guidance to $7.20–$7.30. Revenue and adjusted EPS exceeded FactSet estimates of $1.93 billion and $1.34, respectively.
EQUITY | Nov 05, 2026, 11:02 PM UTC
M
Solventum Posts Q3 Loss, Raises FY26 Adjusted EPS Outlook
Solventum reported a third-quarter loss, largely attributed to lower sales, including the expected reversal of advance customer orders placed in the prior quarter ahead of a planned enterprise resource planning implement
EQUITY | Nov 05, 2026, 10:21 PM UTC
L
Solventum reports third-quarter adjusted EPS of $1.45
EARNINGS | Nov 05, 2026, 09:06 PM UTC
M
Solventum Reports Third-Quarter Sales of $1.9 Billion
Solventum reported sales of $1.9 billion for the third quarter.
EARNINGS | Nov 05, 2026, 09:06 PM UTC
M
Solventum Sees FY Adjusted EPS of $7.20–$7.30
EARNINGS | Nov 05, 2026, 09:05 PM UTC
L
NYSE Reports 130884.0-Share Sell-Side Order Imbalance
EQUITY | Nov 02, 2026, 08:50 PM UTC
H
SOLV says HIS separation keeps 4%-5% organic growth target to 2028
Management said the HIS separation is for strategic focus on medtech, keeping RemainCo’s 4%-5% organic growth target by 2028 intact. Margin dilution is expected, with efficiencies and new launches supporting MedSurg and
EARNINGS | Sep 09, 2026, 04:03 PM UTC
M
SOLV management outlines HIS separation rationale and 2028 growth targets
SOLV management said separating the HIS business improves strategic fit and value creation, reaffirming 4%-5% organic growth targets for 2028 and citing growth drivers, new product launches and margin expansion opportuni
EQUITY | Sep 09, 2026, 03:59 PM UTC
H
SOLV separation of HIS advances MedSurg and Dental focus
Management outlined the rationale for separating the HIS business, citing strategic fit and value creation. It reiterated strong growth and margin outlook for MedSurg and Dental through nearly 20 new product launches thr
EARNINGS | Sep 09, 2026, 03:28 PM UTC
L
SOLV - Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
SOLV - Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
EQUITY | Sep 02, 2026, 08:05 PM UTC
H
Solventum Raises FY2026 Adj EPS Guidance from $6.60 to $7.10-$7.20 vs $6.55 Est
Solventum (NYSE: SOLV ) raises FY2026 Adj EPS guidance from $6.60 to $7.10-$7.20 vs $6.55 analyst estimate..
EARNINGS | Aug 05, 2026, 08:16 PM UTC
H
SOLV - Solventum Reports Second Quarter 2026 Financial Results
SOLV - Solventum Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 08:14 PM UTC
H
Solventum To Separate Health Info Systems
Solventum plans to separate its health information systems business
EQUITY | Aug 05, 2026, 08:05 PM UTC